Arrowstreet Capital
ANIP icon

Arrowstreet Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Arrowstreet Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.5M Sell
562,016
-2,344
-0.4% -$188K 0.02% 594
2026
Q1 		$43.4M Buy
564,360
+91,153
+19% +$7.11M 0.02% 532
2025
Q4 		$37.4M Buy
473,207
+113,029
+31% +$9.79M 0.02% 557
2025
Q3 		$33M Buy
+360,178
New +$29.4M 0.02% 575
2024
Q3 		– Sell
-9,304
Closed -$592K – 1728
2024
Q2 		$592K Buy
9,304
+906
+11% +$58.8K ﹤0.01% 1312
2024
Q1 		$581K Buy
+8,398
New +$507K ﹤0.01% 1428
2022
Q1 		– Sell
-8,538
Closed -$393K – 1178
2021
Q4 		$393K Buy
+8,538
New +$367K ﹤0.01% 1309
2020
Q3 		– Sell
-37,587
Closed -$1.22M – 2312
2020
Q2 		$1.22M Sell
37,587
-55,536
-60% -$1.99M ﹤0.01% 1689
2020
Q1 		$3.79M Sell
93,123
-35,282
-27% -$1.88M 0.01% 840
2019
Q4 		$7.92M Buy
128,405
+122,205
+1,971% +$8.1M 0.02% 686
2019
Q3 		$452K Buy
+6,200
New +$464K ﹤0.01% 1348

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital's ANIP Position: Q2 2026 in Review

Arrowstreet Capital reduced its ANI Pharmaceuticals (ANIP) stake by 0.42% in Q2 2026, selling an estimated $188K and leaving 562,016 shares worth $46.5M. The position accounts for 0.02% of the portfolio, ranked #594.

Arrowstreet Capital first reported a position in ANIP in Q3 2019 and has held it in 11 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Arrowstreet Capital held 562,016 shares of ANI Pharmaceuticals worth $46.5M as of Q2 2026.
  • Arrowstreet Capital sold 2,344 ANI Pharmaceuticals shares in Q2 2026, an estimated $188K.
  • ANI Pharmaceuticals made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #594 holding.
  • Arrowstreet Capital first reported a position in ANI Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.